At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Ifetroban +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled Pilot Study to Assess the Safety and Efficacy of Ifetroban for the Treatment of Portal Hypertension in Cirrhotic Patients
In Brief
A Phase 2 clinical trial evaluating Ifetroban and Placebo for Portal Hypertension and Liver Cirrhosis. Completed, enrolled 30 participants across 6 sites.
Detailed Summary
This placebo-controlled study will assess the safety and efficacy of a 90-day course of treatment with ifetroban for portal hypertension in cirrhotic patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPortal Hypertension, Liver Cirrhosis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartMar 2017
Primary CompletionJul 2018
TodayJul 2026
First PostedJun 16, 2016
Enrollment StartMar 6, 2017
Primary CompletionJul 17, 2018
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.0 years ago
Interventions
Ifetrobandrug
thromboxane prostanoid receptor antagonist delivered as infusion and oral capsule
Placebodrug
matched placebo delivered as infusion and oral capsule